Due to severe air pollution, the demands for eye drop are radically increasing in China where Houns
eye drop manufacturing factory is distinctively standing. To stake out a position in the Chinese eye
drop market, which value is estimated to be 1.4 trillion won, Houns founded its factory in Beijing for
the first time among Korean pharmaceutical companies. In July 2014, it finished founding Beijing
Huonland Pharmaceutical co., LTD., and began to operate facilities in 2015.
Kynex, hyaluronic acid artificial eye drop without preservative that Houns produces, are being sold through world-class ophthalmology business firms and take the largest market share in Korea. Having cGMP-level Jecheon factory, Houns is holding excellent technologies and knowhow enough to build the factory that fulfill enhanced standards.
The production capacity for mono dose in the factory amounts to 270 thousand bottles per day and 70 million bottles per year while that for Multidose reaches to 140 thousand bottles per day and to 35 million bottles per year.
To HUONLAND, we will concentrate our experience of developing the first plastic injection container in Korea, technological capability of Kynex that takes the largest market share in the artificial eye drop without preservative, and production capacity underlying cGMP-level factory in Jecheon.